

Supplementary Table 3. Sonazoid-enhanced US features for 31 histologically proven lesions

	Total	Histologically proven lesions		P-value
		HCC (n=23)	Non-HCC (n=8)	
AP				0.256
Hyperenhancement	23	18 (78.3)	5 (62.5)	
Isoenhancement	6	3 (13.0)	3 (37.5)	
Hypoenhancement	2	2 (8.7)	0	
PVP				0.550
Hyperenhancement	2	1 (4.3)	1 (12.5)	
Isoenhancement	13	9 (39.1)	4 (50.0)	
Hypoenhancement	16	13 (56.5)	3 (37.5)	
LP				0.028
Hyperenhancement	1	0	1 (12.5)	
Isoenhancement	5	2 (8.7)	3 (37.5)	
Hypoenhancement	25	21 (91.3)	4 (50.0)	
KP				0.177
Hyperenhancement	0	0	0	
Isoenhancement	5	2 (8.7)	3 (37.5)	
Hypoenhancement	26	21 (91.3)	5 (62.5)	
Pattern of wash-in				
In-whole or in-part	21	17 (73.9)	4 (50.0)	0.231
Rim	1	0	1 (12.5)	
Stellate vessels	1	1 (4.3)	0	
Not applicable	8	5 (21.7)	3 (37.5)	
Washout first appeared				0.100
Hyper-/isoenhancement in AP	29			
From PVP	14	11 (47.8)	3 (37.5)	
From LP	9	8 (34.8)	1 (12.5)	
From KP	1	0	1 (12.5)	
No washout	5	2 (8.7)	3 (37.5)	
Hypoenhancement in all phase	2	2 (8.7)	0	
CEUS LI-RADS major and ancillary features and Kupffer phase defect				
Arterial phase hyperenhancement	22	18 (78.3)	4 (50.0)	0.185 ^{a)}
Late and mild washout	22	19 (82.6)	4 (50.0)	0.154 ^{a)}
Kupffer phase defect	26	21 (91.3)	5 (62.5)	0.093 ^{a)}
Nodule-in-nodule or mosaic	10	9 (39.1)	1 (12.5)	0.222 ^{a)}
CEUS LR-M criteria				
Rim APHE	1	0	1 (12.5)	NA
Early washout	0	0	0	NA
Marked washout	0	0	0	NA

Values are presented as number (%) unless otherwise indicated.

US, ultrasonography; HCC, hepatocellular carcinoma; AP, arterial phase; PVP, portal venous phase; LP, late phase; KP, Kupffer phase; CEUS, contrast-enhanced ultrasonography LI-RADS, Liver Imaging Reporting and Data System; APHE, arterial phase hyperenhancement; NA, not applicable.

^{a)}Fisher exact test.